Gut

Article	Citations
Growth rates and histopathological outcomes of small (6–9 mm) colorectal polyps based on CT colonography surveillance and endoscopic removal	1370
Defining the key intrahepatic gene networks in HCV infection driven by sex	1002
Picking up microbial clues in early-onset colorectal cancer	748
Finding a mate for MLCK: improving the potential for therapeutic targeting of gut permeability	426
Genetically proxied ketohexokinase function and risk of colorectal cancer: a Mendelian randomisation study	319
Liquid biopsy to identify Barrett’s oesophagus, dysplasia and oesophageal adenocarcinoma: theEMERALDmulticentre study	305
Innumerable nodules in all parts of the small intestine	294
Immunomodulation and entry inhibition: selgantolimod’s double punch against hepatitis B virus	257
Unusual history of ‘stitch’	189
Response to McAlindon’s letter	188
Unusual case of severe diarrhoea	183
Rate of suitable cases for primary EUS-guided biliary drainage in distal malignant biliary obstruction	182
Correction:P97 A patient information bundle outlining dietary advice in liver disease specific to the cost of living crisis improves patient care: ‘Looking after Your Liver for Less’	182
Perturbation of mRNA splicing in liver cancer: insights, opportunities and challenges	180
Prospective, double-blind diagnostic multicentre study of confocal laser endomicroscopy for wheat sensitivity in patients with irritable bowel syndrome	168
Gut virome-colonisingOrthohepadnavirusgenus is associated with ulcerative colitis pathogenesis and induces intestinal inflammationin vivo	165
Where are we with gastric cancer screening in Europe in 2024?	162
Impact of margin thermal ablation after endoscopic mucosal resection of large (≥20 mm) non-pedunculated colonic polyps on long-term recurrence	161
Reducing low risk of transmissible infection in duodenoscopes: at what cost to the planet?	161
Automated sizing of colorectal polyps using computer vision	157
HBcrAg values may predict virological and immunological responses to pegIFN-α in NUC-suppressed HBeAg-negative chronic hepatitis B	153
IL-3 receptor signalling suppresses chronic intestinal inflammation by controlling mechanobiology and tissue egress of regulatory T cells	152
Mass cytometry-based peripheral blood analysis as a novel tool for early detection of solid tumours: a multicentre study	149
Third Asia-Pacific consensus recommendations on colorectal cancer screening and postpolypectomy surveillance	145
Holistic healthcare in inflammatory bowel disease: time for patient-centric approaches?	145

S100A10 promotes HCC development and progression via transfer in extracellular vesicles and regulating their protein cargos	142
A mucus production programme promotes classical pancreatic ductal adenocarcinoma	141
Absence of a pancreatic microbiome in intraductal papillary mucinous neoplasm	140
COVID-19 and liver disease	138
Establishment of enterically transmitted hepatitis virus animal models using lipid nanoparticle-based full-length viral genome RNA delivery system	134
Autologous regulatory T-cell transfer in refractory ulcerative colitis with concomitant primary sclerosing cholangitis	133
Methionine deficiency facilitates antitumour immunity by altering m6A methylation of immune checkpoint transcripts	132
Current therapies and new developments in NASH	130
Sugar-sweetened beverage intake in adulthood and adolescence and risk of early-onset colorectal cancer among women	127
Definite benefits of GLP-1 receptor agonists: what is the risk of gastroparesis and lung aspiration?	126
Perplexing case of abdominal pain with eosinophilia and fasciitis	125
Selective decontamination of the digestive tract in critically ill children: fighting fire with fire or burning down the house?	125
Impact of climate change on vulnerable populations	120
24-Nor-ursodeoxycholic acid improves intestinal inflammation by targeting TH17 pathogenicity and transdifferentiation	119
Engineered anti-PDL1 with IFNα targets both immunoinhibitory and activating signals in the liver to break HBV immune tolerance	119
Response to the letter to the editor	118
Correction: Inflammatory cell-derived CXCL3 promotes pancreatic cancer metastasis through a novel myofibroblast-hijacked cancer escape mechanism	118
Interactive enhancer hubs (iHUBs) mediate transcriptional reprogramming and adaptive resistance in pancreatic cancer	116
Sodium+/taurocholate cotransporting polypeptide as target therapy for liver fibrosis	116
Intron-mediated enhancement of SPINK1 expression for pancreatitis therapy	116
Tumour-intrinsic alterations and stromal matrix remodelling promote Wnt-niche independence during diffuse-type gastric cancer progression	115
GI highlights from the literature	114
Reply to: Non-invasive tests and advanced chronic liver disease in NAFLD: two steps forward and one step back?	106
Tiny contributors to severe obesity inside the gut	104
From clinical trials to clinical practice: how should we design and evaluate prediction models in the care of IBD?	102
Shaggy white lesion with morphological changes in the oesophagus	102
Humoral response to SARS-CoV-2 infection among liver transplant recipients	101
Host transcriptome signatures in human faecal-washes predict histological remission in patients with IBD	100
Faecal occult blood loss accurately predicts future detection of colorectal cancer. A prognostic model	99
Most excess years of potential life loss among individuals with cirrhosis during the pandemic were not related to COVID-19	99
Lumen-apposing metal stents versus double-pigtail plastic stents for infected necrotising pancreatitis: more doubts than answers	98
Time for arginine methylation: PRMT5 inhibition to advance cholangiocarcinoma treatment	95
Discovery of the pancreatic basal cell: a new candidate for an adult stem cell emerges	93
Need for standardised approaches to human microbiome research using the example of colorectal neoplasia research	91
GI highlights from the literature	91
Association between appendectomy and Parkinson’s disease from the UK Biobank	90
Rare cause of obstructive jaundice	89
New entity of adult ultra-short coeliac disease: the first international cohort and case–control study	89
British Society of Gastroenterology guidelines on sedation in gastrointestinal endoscopy	88
Reflux conditions induce E-cadherin cleavage and EMT via APE1 redox function in oesophageal adenocarcinoma	88
Unveiling 8 years of duodenoscope contamination: insights from a retrospective analysis in a large tertiary care hospital	86
Extracellular Vesicles from Pancreatic Cancer Stem Cells Lead an Intratumor Communication Network (EVNet) to fuel tumour progression	85
Integrated multimodel analysis of intestinal inflammation exposes key molecular features of preclinical and clinical IBD	85
MicroRNA-223 attenuates hepatocarcinogenesis by blocking hypoxia-driven angiogenesis and immunosuppression	84
APCmosaicism, not always isolated: two first-degree relatives with apparently distinctAPCmosaicism	83
Endoscopic stratification of gastric intestinal metaplasia: where are we, where do we want to go and how do we get there?	82
SARS-CoV-2 vaccination in patients with GI and hepatobiliary carcinoma: a call for booster vaccination	80
Environmental and healthcare trade-offs between single-use and reusable gastroscopes	79
Treatment of type 2 diabetes with MASLD: new evidence for personalised medicine	79
Rethinking routine mapping biopsies in gastric intestinal metaplasia: justification for endoscopic stratification	78

Enolase represents a metabolic checkpoint controlling the differential exhaustion programmes of hepatitis virus-specific CD8+T cells	78
Fasting-mimicking diet-enrichedBifidobacterium pseudolongumsuppresses colorectal cancer by inducing memory CD8+T cells	77
Withdrawal of the British Society of Gastroenterology IBD risk grid for COVID-19 severity	77
Dietary fibres and IBS: translating functional characteristics to clinical value in the era of personalised medicine	76
Postprandial symptoms in disorders of gut-brain interaction and their potential as a treatment target	76
Immunopathogenesis and environmental triggers in coeliac disease	76
Targeting hepatic stellate cells to combat liver fibrosis: where do we stand?	74
Ebastine for the treatment of irritable bowel syndrome: old drug, new tricks?	73
GI highlights from the literature	73
British Society of Gastroenterology interim framework for addressing the COVID-19-related backlog in inflammatory bowel disease colorectal cancer surveillance	72
Comparison between non-pulmonary and pulmonary immune responses in a HIV decedent who succumbed to COVID-19	71
Endoscopic papillectomy versus surgical ampullectomy for adenomas and early cancers of the papilla: a retrospective Pancreas2000/European Pancreatic Club analysis	69
Correction: Prevalence of irritable bowel syndrome and functional dyspepsia after acute gastroenteritis: systematic review and meta-analysis	69
Impact of age, comorbidities and relevant changes on surveillance strategy of intraductal papillary mucinous neoplasms: a competing risk analysis	68
Targeting MS4A4A on tumour-associated macrophages restores CD8+ T-cell-mediated antitumour immunity	65
Association between inflammatory bowel disease and Alzheimer’s disease: multivariable and bidirectional Mendelian randomisation analyses	65
FSTL1 promotes liver fibrosis by reprogramming macrophage function through modulating the intracellular function of PKM2	65
Porcine-derived pancreatic enzyme replacement therapy may be linked to chronic hepatitis E virus infection in cystic fibrosis lung transplant recipients	64
Hypophosphataemia following ferric derisomaltose and ferric carboxymaltose in patients with iron deficiency anaemia due to inflammatory bowel disease (PHOSPHARE-IBD): a randomised clinical trial	64
Unannotated small RNA clusters associated with circulating extracellular vesicles detect early stage liver cancer	64
GI highlights from the literature	63
Submucosal steroid pre-injection strategy to prevent oesophageal stricture after circumferential endoscopic submucosal dissection	63
GI highlights from the literature	62
Fatal intestinal disease: a case of recurrent lower gastrointestinal bleeding	62
Molecular portraits of patients with intrahepatic cholangiocarcinoma who diverge as rapid progressors or long survivors on chemotherapy	62
Methods for handling missing segments in Crohn’s disease clinical trials: analysis from the EXTEND trial	61
Gut check: can other microbes or communities phenocopyH. pylori’s early gastric pathology?	61
It takes two to TAM-go	60
Clinical relevance of biomarkers in cholangiocarcinoma: critical revision and future directions	58
Quest for HBV functional cure: what have we learnt from silencing RNAs?	57
National Institute for Health and Care Excellence (NICE) guidance on monitoring and management of Barrett’s oesophagus and stage I oesophageal adenocarcinoma	57
Unravelling the obesity paradox in MASLD patients with extrahepatic cancer	57
Response letter to the editor	57
Spatial dissection of tumour microenvironments in gastric cancers reveals the immunosuppressive crosstalk betweenCCL2+fibroblasts andSTAT3-activated macrophages	56
NFATc1 signaling drives chronic ER stress responses to promote NAFLD progression	55
MED12 loss activates endogenous retroelements to sensitise immunotherapy in pancreatic cancer	55
Abnormal gastrointestinal motility is a major factor in explaining symptoms and a potential therapeutic target in patients with disorders of gut–brain interaction	54
Gastric emptying study before gastric peroral endoscopic myotomy (G-POEM): can intragastric meal distribution be a predictor of success?	54
Non-invasive assessment of MASH resolution	54
Severity of gastric intestinal metaplasia predicts the risk of gastric cancer: a prospective multicentre cohort study (GCEP)	54
Understanding the malignant potential of gastric metaplasia of the oesophagus and its relevance to Barrett’s oesophagus surveillance: individual-level data analysis	53
Monocyte phenotypic liquid biopsy for NASH and liver fibrosis diagnosis: a new kid on the block	53
Comparison of drugs for active eosinophilic oesophagitis: systematic review and network meta-analysis	52
Human enteric nervous system progenitor transplantation improves functional responses in Hirschsprung disease patient-derived tissue	52
Cultivated human intestinal fungusCandida metapsilosisM2006B attenuates colitis by secreting acyclic sesquiterpenoids as FXR agonists	51
Response by Abrahami et al to letter regarding article ‘Proton pump inhibitors and risk of colorectal cancer’	51
GI highlights from the literature	50
Diagnostic dilemma: a patient with diarrhoea	49
Combining epigenetic modulation: the next step for HCC immunotherapy?	48
Targeting MYC effector functions in pancreatic cancer by inhibiting the ATPase RUVBL1/2	48
Prevalence of irritable bowel syndrome and functional dyspepsia after acute gastroenteritis: systematic review and meta-analysis	48
Dominant-negative effect of lactase missense variants: hetero-complex assembly with the wild-type enzyme impairs intracellular trafficking and digestive function	47
Targeting TL1A and DR3: the new frontier of anti-cytokine therapy in IBD	47
Correction:PMO-29 Switching between infliximab biosimilars: experience from two inflammatory bowel disease centres	47
Autologous T cell responses to primary human colorectal cancer spheroids are enhanced by ectonucleotidase inhibition	47
Gut microbiota as non-invasive diagnostic and prognostic biomarkers for natural killer/T-cell lymphoma	47
Hepatic TM6SF2 activates antitumour immunity to suppress metabolic dysfunction-associated steatotic liver disease-related hepatocellular carcinoma and boosts immunotherapy	47
Risk of metachronous advanced neoplasia in patients with serrated lesions depending on follow-up schedule	47
NNMT enriches for AQP5+cancer stem cells to drive malignant progression in early gastric cardia adenocarcinoma	46
Altered faecal microbiome and metabolome in IgG4-related sclerosing cholangitis and primary sclerosing cholangitis	46
Uniting the global gastroenterology community to meet the challenge of climate change and non-recyclable waste	46
Targeting ER protein TXNDC5 in hepatic stellate cell mitigates liver fibrosis by repressing non-canonical TGFβ signalling	46
Long-term hepatitis B surface antigen response after finite treatment of ARC-520 or JNJ-3989	46
IL-20 subfamily cytokines impair the oesophageal epithelial barrier by diminishing filaggrin in eosinophilic oesophagitis	45
Assessment of the yearly carbon emission of a gastrointestinal endoscopy unit	45
Synergistic association of sodium-glucose cotransporter-2 inhibitor and metformin on liver and non-liver complications in patients with type 2 diabetes mellitus and metabolic dysfunction-associated st	45
Evaluation of proton pump inhibitors and risks of gastric cancer	44
Combining dietary fibres to reduce intestinal gas production in patients with IBS	44
Interplay between diet, circulating indolepropionate concentrations and cardiometabolic health in US populations	44
The road to a world-unified approach to the management of patients with gastric intestinal metaplasia: a review of current guidelines	44
Human milk oligosaccharide 2’-fucosyllactose protects against high-fat diet-induced obesity by changing intestinal mucus production, composition and degradation linked to changes in gut microbiota and	44
Landscape of the gut mycobiome dynamics during pregnancy and its relationship with host metabolism and pregnancy health	43
Lysosomal lipid switch sensitises to nutrient deprivation and mTOR targeting in pancreatic cancer	43
Single-cell sequencing unveils distinct immune microenvironments with CCR6-CCL20 crosstalk in human chronic pancreatitis	43
Long-term use of proton pump inhibitors (PPIs) is associated with an increased risk of type 2 diabetes	43
APCandP53mutations synergise to create a therapeutic vulnerability to NOTUM inhibition in advanced colorectal cancer	43
Fungi and cancer	42
Human and preclinical studies of the host–gut microbiome co-metabolite hippurate as a marker and mediator of metabolic health	42
Global prevalence of non-alcoholic fatty liver disease in type 2 diabetes mellitus: an updated systematic review and meta-analysis	42
The Peptidoglycan Recognition Protein 1 confers immune evasive properties on pancreatic cancer stem cells	42

Sex-based differences in prescribed medications, surgical procedures and disease-related complications in IBD	41
Correction:Sympathetic nervous activation, mitochondrial dysfunction and outcome in acutely decompensated cirrhosis: the metabolomic prognostic models (CLIF-C MET)	40
GI snapshot: arrhythmia, dysphagia and weight loss in a 71-year-old man	40
Correction: Macrophages direct cancer cells through a LOXL2-mediated metastatic cascade in pancreatic ductal adenocarcinoma	40
Eosinophils: a novel therapeutic target to promote liver regeneration in acute liver injury?	40
Correction:O4 Acceptability and feasibility of a multimodal early detection pilot study for liver disease in high risk groups: “Alright My Liver?”	40
Specific gut pathobionts escape antibody coating and are enriched during flares in patients with severe Crohn’s disease	39
Antibody response to the BNT162b2 SARS-CoV-2 vaccine in paediatric patients with inflammatory bowel disease treated with anti-TNF therapy	39
Is the significant risk of perioperative complications associated with radical surgery following non-curative endoscopic submucosal dissection for early colorectal cancer still acceptable?	39
Is HBx protein the X factor in the pathogenesis of IBD?	39
GI highlights from the literature	39
Establishment of a validated central reading system for ileocolonoscopy in an academic setting	39
Tailoring treatment to the circumstance: reasoning behind metal versus plastic drainage of pancreatic collections	39
HBV integrations reshaping genomic structures promote hepatocellular carcinoma	38
Trends and cross-country inequality in the incidence of GI cancers among the working-age population from 1990 to 2021: a Global Burden of Disease 2021 analysis	38
Variceal band ligation and carvedilol: together forever, or not?	38
Maternal obesity, pregnancy weight gain, and birth weight and risk of colorectal cancer	38
Vessel and tissue recognition during third-space endoscopy using a deep learning algorithm	38
Single-cell omics in inflammatory bowel disease: recent insights and future clinical applications	38
Nuclear translocation of plasma membrane protein ADCY7 potentiates T cell-mediated antitumour immunity in HCC	37
Gut microbiome and dietary fibre intake strongly associate with IgG function and maturation following SARS-CoV-2 mRNA vaccination	36
Alcohol exhibits contrasting effects on CD8+T cells in the gut and liver in alcohol-associated liver disease	36
Recent advances in incretin-based therapy for MASLD: from single to dual or triple incretin receptor agonists	36
Multiomics reveal unique signatures of human epiploic adipose tissue related to systemic insulin resistance	35
Effectiveness of mailed outreach and patient navigation to promote HCC screening process completion: a multicentre pragmatic randomised clinical trial	34
Simplified Helicobacter pylori therapy for patients with penicillin allergy: a randomised controlled trial of vonoprazan-tetracycline dual therapy	33
Maternal antibiotic exposure during pregnancy and risk of IBD in offspring: a population-based cohort study	33
Artificial intelligence applied to ‘omics data in liver disease: towards a personalised approach for diagnosis, prognosis and treatment	33
Precancerous nature of intestinal metaplasia with increased chance of conversion and accelerated DNA methylation	33
Basal levels of microbiota-driven subclinical inflammation are associated with anastomotic leak in patients with colorectal cancer	33
Estimating the environmental impact of disposable endoscopic equipment and endoscopes	33
Phenotypic CD8 T cell profiling in chronic hepatitis B to predict HBV-specific CD8 T cell susceptibility to functional restoration in vitro	33
Organoids in gastrointestinal diseases: from experimental models to clinical translation	32
British Society of Gastroenterology guidelines for the diagnosis and management of cholangiocarcinoma	32
What to do about the leaky gut	32
Endocytoscopy with automated multispectral intestinal barrier pathology imaging for assessment of deep healing to predict outcomes in ulcerative colitis	32
DYRK1B blockade promotes tumoricidal macrophage activity in pancreatic cancer	32
Integrated analysis of the faecal metagenome and serum metabolome reveals the role of gut microbiome-associated metabolites in the detection of colorectal cancer and adenoma	31
Combining ferroptosis induction with MDSC blockade renders primary tumours and metastases in liver sensitive to immune checkpoint blockade	31
Cold versus hot snare endoscopic mucosal resection for large (≥15 mm) flat non-pedunculated colorectal polyps: a randomised controlled trial	31
Cellular immunotherapies and immune cell depleting therapies in inflammatory bowel diseases: the next magic bullet?	31
SARS-CoV-2 Omicron variant infection was associated with higher morbidity in patients with cirrhosis	31
Alterations to the duodenal microbiota are linked to gastric emptying and symptoms in functional dyspepsia	30
Alternative splicing of viral transcripts: the dark side of HBV	30
Liver stiffness thresholds to predict disease progression and clinical outcomes in bridging fibrosis and cirrhosis	30
Gnotobiotic mice housing conditions critically influence the phenotype associated with transfer of faecal microbiota in a context of obesity	29
Patient-reported experience of colonoscopy in Italy: a multicentre prospective observational study	29
Proton pump inhibitors and gastric cancer: a population-based cohort study	29
Stool microRNA profiling— dumpster diving for a master marker?	29
Reply to Newmanet al‘Response to epidemiology of inflammatory bowel disease in men with high-risk homosexual activity’	29
Unusual cause of abdominal pain	29
Porcine-derived pancreatic enzyme replacement therapy: a cause of hepatitis E virus transmission?	29
More than meets the eye: a strange cause of bowel obstruction and perforation	29
Key metabolomic alterations are associated with ulcerative colitis disease state and activity: a validation analysis	29
Genetic and transcriptomic landscape of colonic diverticulosis	29
CAF-macrophage crosstalk in tumour microenvironments governs the response to immune checkpoint blockade in gastric cancer peritoneal metastases	29
Stressed hepatocyte sustains alcohol-associated hepatitis progression by producing leukocyte cell-derived chemotaxin 2	29
Presenilins: the hidden guardians of gut health in Alzheimer’s disease	28
Ferritin—a promising biomarker in MASLD	28
Germline mutations and pancreatic cancer risk in chronic pancreatitis	28
Intravital imaging: dynamic insights into liver immunity in health and disease	28
Suppressor CD4+T cells expressing HLA-G are expanded in the peripheral blood from patients with acute decompensation of cirrhosis	28
Correction:Residual SARS-CoV-2 viral antigens detected in GI and hepatic tissues from five recovered patients with COVID-19	28
Purified oat protein can trigger acute symptoms linked to immune activation in coeliac disease patients but not histological deterioration	28
Pancreatic cancer surveillance and its ongoing challenges: is it time to refine our eligibility criteria?	28
An unusual cause of oesophageal stricture	28
Correction:O11 Utilising peer support workers in hepatitis C screening in emergency departments: a pilot study	28
Patient selection for urgent endoscopic retrograde cholangio-pancreatography by endoscopic ultrasound in predicted severe acute biliary pancreatitis (APEC-2): a multicentre prospective study	27
MAFLD, HCC and the dilemma of (changing) terminology in liver diseases	27
Is the biogeography of the mucosa-associated microbiota a key factor affecting primary sclerosing cholangitis disease course and treatment?	27
DNA-methylation signature accurately differentiates pancreatic cancer from chronic pancreatitis in tissue and plasma	26
Accuracy of measuring colorectal polyp size in pathology: a prospective study	26
Over-the-scope-clips versus standard treatment in high-risk patients with acute non-variceal upper gastrointestinal bleeding: a randomised controlled trial (STING-2)	26
Efficacy of biological therapies and small molecules in moderate to severe ulcerative colitis: systematic review and network meta-analysis	26
Post-acute COVID-19 syndrome and gut dysbiosis linger beyond 1 year after SARS-CoV-2 clearance	26
Clinical outcome of non-curative endoscopic submucosal dissection for early colorectal cancer	26
CRIP1 fosters MDSC trafficking and resets tumour microenvironment via facilitating NF-κB/p65 nuclear translocation in pancreatic ductal adenocarcinoma	25
Mapping the human gut mycobiome in middle-aged and elderly adults: multiomics insights and implications for host metabolic health	25
GM-CSF drives myelopoiesis, recruitment and polarisation of tumour-associated macrophages in cholangiocarcinoma and systemic blockade facilitates antitumour immunity	25
eCura and W-eCura: different scores, different populations, same goal	25
Faecal immunochemical testing (FIT) in patients with signs or symptoms of suspected colorectal cancer (CRC): a joint guideline from the Association of Coloproctology of Great Britain and Ireland (ACPG	25
Omega-3 polyunsaturated fatty acids: moving towards precision use for prevention and treatment of colorectal cancer	25
Cold versus hot EMR for large duodenal adenomas	25
Inhibition of YTHDF1 by salvianolic acid overcomes gluten-induced intestinal inflammation	25
Long-term liver-related outcomes and liver stiffness progression of statin usage in steatotic liver disease	25
Global prevalence of ultra-short coeliac disease (USCD): the first systematic review and meta-analysis	24
Correction:Growth differentiation factor 11 attenuates liver fibrosis via expansion of liver progenitor cells	24
Severe multiple therapy refractory colitis in a 46-year-old man	24
Response to: Correspondence on "PICaSSO Histologic Remission Index (PHRI) in ulcerative colitis: development of a novel simplified histological score for monitoring mucosal healing and predicting clin	24
Large proximal gastric GIST tumours: downsizing by imatinib and subsequent endoresection	24
Short-chain fatty acids in patients with severe acute pancreatitis: friend or foe?	24
GI highlights from the literature	23
Undiagnosed inflammatory bowel disease among individuals undergoing colorectal cancer screening: a nationwide Danish cohort study 2014–2018	23
GI highlights from the literature	23
GI highlights from the literature	23